CCMI
LGND icon

Creative Capital Management Investments’s Ligand Pharmaceuticals LGND Stock Holding History

Creative Capital Management Investments’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$632 Buy
+2
New +$471 ﹤0.01% 1221

Other funds holding LGND

CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
CCM
Context Capital Management Lajolla, California $5.15B AUM 1.28% 1-Year Est. Return
PM
Pembroke Management Montreal, Quebec, Canada $637M AUM 40.98% 1-Year Est. Return
MAP
Moody Aldrich Partners Marblehead, Massachusetts $557M AUM 122.79% 1-Year Est. Return
New York State Teachers Retirement System (NYSTRS)
New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return
IP
Isthmus Partners Madison, Wisconsin $1.03B AUM 22.86% 1-Year Est. Return
WC
Woodstock Corp Boston, Massachusetts $1.2B AUM 26.37% 1-Year Est. Return
MNBTD
Moody National Bank Trust Division Galveston, Texas $1.21B AUM 38.93% 1-Year Est. Return
CPC
Cookson Peirce & Co Pittsburgh, Pennsylvania $3.04B AUM 94.11% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

Creative Capital Management Investments's LGND Position: Q2 2026 in Review

Creative Capital Management Investments opened a new position in Ligand Pharmaceuticals (LGND) in Q2 2026: 2 shares worth $632. The stake represents ﹤0.01% of the portfolio and ranks #1221 among its holdings.

83 funds tracked by Wall St. Rank hold LGND as of Q2 2026.

  • Creative Capital Management Investments held 2 shares of Ligand Pharmaceuticals worth $632 as of Q2 2026.
  • Ligand Pharmaceuticals was a new Creative Capital Management Investments position in Q2 2026.
  • Ligand Pharmaceuticals made up ﹤0.01% of Creative Capital Management Investments's portfolio in Q2 2026, its #1221 holding.
  • 83 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.

Based on Creative Capital Management Investments's 13F filing for Q2 2026, filed 24 Jul 2026.